3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors
Leave reply:
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Follow Kairos Ventures on LinkedIn
Subscribe to Kairos News
Recent Posts
- PteroDynamics Raises $7.5 Million Seed Round to Expand Transwing Aircraft Platform
- Tempus Announces New Multi-omics Collaboration with Actuate Therapeutics
- Why Kairos Ventures Is Betting Big On ‘Omics’ To Power The Biotech Revolution
- Podcast: Commercial-ready plasma-based aftertreatment and ignition
- Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma